Rulli E, et al. - Researchers sought to elucidate the activity and efficacy of targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy or not, which are commonly used in patients with melanoma brain metastases. Conducting a systematic search of MEDLINE, Embase, and conference proceedings up to January 2019, they included a total of 15 trials that provided 1132 patients for analyses. As per findings, CMI vs MI and combination TT results in increased long-term progression-free survival and overall survival. Combination TT and CMI resulted in similar intracranial response rate.